CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study

Table 3 Thromboembolic potential of different anti-CD40L antibody formats in a comparative 8-week study in Rhesus monkeys

Dose group (n)	Total animals affected (%)	Total affected lung sections	Total examined lung sections	Lung sections affected (%)
Historic saline controls	7 (50)	10	406	2.5
(n = 14)^a	7 (50)	10	406	2.5
Concurrent saline control	1 (25)	1	116	0.9
(n = 2/sex)^a	1 (25)	1	116	0.9
CDP7657	3 (37.5)	4	232 (203)^c	1.7 (2.0)^c
(n = 4/sex)^b	3 (37.5)	4	232 (203)^c	1.7 (2.0)^c
Aglycosyl hu5c8	3 (37.5)	3	232	1.3
(n = 4/sex)	3 (37.5)	3	232	1.3
Hu5c8	5 (62.5)	41	232	17.6
(n = 4/sex)	5 (62.5)	41	232	17.6

Thrombembolic events were defined as the occurrence of thrombus, an organizing thrombus or intimal hyperplasia. ^aHistoric control group of Rhesus monkeys that had received i.v. saline for up to 6 months; ^bone animal died on day 2, which was unrelated to CDP7657 treatment; ^cvalues in parentheses do not include animals removed from the study for humane reasons unrelated to the study

ISSN: 1478-6362